Bristol-Myers Squibb Company - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BMY New York 2830 www.bms.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth - Feb 12th, 2026 2:42 am
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call - Feb 11th, 2026 10:38 pm
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight - Feb 11th, 2026 3:31 pm
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Feb 11th, 2026 7:00 am
Robert A. Winn Excellence in Clinical Trials Award Program Announces Third Cohort of Physician-Researchers for the Clinical Investigator Leadership Award - Feb 11th, 2026 5:00 am
Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound? - Feb 10th, 2026 9:15 am
Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line? - Feb 10th, 2026 9:06 am
Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline Outlook - Has The Bull Case Changed? - Feb 10th, 2026 5:11 am
Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation - Feb 9th, 2026 7:12 pm
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Feb 9th, 2026 4:14 pm
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Feb 9th, 2026 8:29 am
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Feb 9th, 2026 6:33 am
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Feb 8th, 2026 11:00 pm
Bristol Myers price target raised to $40 from $37 at Morgan Stanley - Feb 7th, 2026 8:45 am
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Feb 7th, 2026 8:08 am
Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. - Feb 6th, 2026 10:01 am
What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)? - Feb 6th, 2026 8:09 am
BMS reports flat revenue growth for full-year 2025 - Feb 6th, 2026 4:48 am
Bristol Myers Squibb Q4 Earnings Call Highlights - Feb 6th, 2026 2:27 am
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Feb 5th, 2026 10:34 pm